Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Titles
NEW
 Top 50 Non-Healthcare Titles
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Transthyretin Amyloidosis Treatment Global Market Report 2025
Request Sample Buy Now
Global Transthyretin Amyloidosis Treatment Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Transthyretin Amyloidosis Treatment Global Market Report 2025

By Type (Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)), By Drug (Tafamidis, Patisiran, Inotersen, Other Drugs), By Therapy (Targeted Therapy, Supportive Therapy, Pipeline Therapy), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Transthyretin Amyloidosis Treatment Market Overview

• Transthyretin Amyloidosis Treatment market size has reached to $4.59 billion in 2024

• Expected to grow to $6.83 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%

• Growth Driver: Increased Research And Development Investments Propel Growth In The Transthyretin Amyloidosis Treatment Market

• Market Trend: Innovative Orphan Drug Combinations Transforming The Landscape Of Transthyretin Amyloidosis Treatment

• North America was the largest region in 2024.

What Is Covered Under Transthyretin Amyloidosis Treatment Market?

Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal protein deposits in the body's organs and tissues. Transthyretin amyloidosis treatment refers to the medical interventions and therapeutic strategies designed to manage and mitigate the effects of transthyretin amyloidosis (ATTR).

The main types of transthyretin amyloidosis treatment include transthyretin amyloidosis with polyneuropathy (ATTR-PN) and transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Transthyretin amyloidosis with polyneuropathy (ATTR-PN) refers to a type of amyloidosis characterized by the deposition of abnormal transthyretin protein in nerves, leading to peripheral neuropathy and other neurological symptoms. These disease types are treated with drugs such as tafamidis, patisiran, inotersen, and others, along with targeted therapy, supportive therapy, and pipeline therapies, which are distributed through channels including Hospital Pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies.

Transthyretin Amyloidosis Treatment Market Size and growth rate 2025 to 2029: Graph

What Is The Transthyretin Amyloidosis Treatment Market Size 2025 And Growth Rate?

The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $4.59 billion in 2024 to $4.96 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research.

What Is The Transthyretin Amyloidosis Treatment Market Growth Forecast?

The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $6.83 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, improved access to treatment. Major trends in the forecast period include emergence of combination therapies, strategic partnerships for drug development, focus on targeting peripheral and cardiac manifestations, implementation of patient education programs, incorporation of real-world evidence in treatment guidelines.

The forecast of 8.3% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. specialty care by increasing the price of gene-silencing RNAi therapeutics (patisiran/inotersen) manufactured in Ireland and Italy, thereby limiting access to disease-modifying treatments and elevating amyloidosis clinic budgets. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Transthyretin Amyloidosis Treatment Market Segmented?

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs

3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy

4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN

2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM

What Is Driving The Transthyretin Amyloidosis Treatment Market? Increased Research And Development Investments Propel Growth In The Transthyretin Amyloidosis Treatment Market

Rising investments in research and development are expected to propel the growth of the transthyretin amyloidosis treatment market going forward. Research and development (R&D) investments include financial resources allocated to activities aimed at advancing scientific knowledge, developing new technologies, creating innovative products, and improving existing processes. Increased funding in research and development enables the discovery and development of innovative treatment approaches for transthyretin amyloidosis, including novel drugs, gene therapies, and precision medicine techniques, offering patients more effective and targeted treatment options. For instance, in December 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company engaged in the development of Vutrisiran, a treatment of ATTR amyloidosis, increased its research and development investment to $883,015 in 2022 from $792,156 in 2021, reflecting a growth of 11.49%. Therefore, the rising investment in research and development will drive the growth of the transthyretin amyloidosis treatment industry.

What Is Driving The Transthyretin Amyloidosis Treatment Market? Aging Population Demographics Fuel Growth In Transthyretin Amyloidosis Treatment Market

The rising aging population demographic is expected to propel the growth of the transthyretin amyloidosis treatment market going forward. An aging population refers to a demographic shift in which the median age of a population increases due to declining fertility rates and rising life expectancy. Aging is a significant risk factor for transthyretin amyloidosis (ATTR), and as the population ages, there is a higher prevalence of Transthyretin Amyloidosis cases. This leads to a growing patient pool in need of treatment. For instance, in October 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations responsible for international public health, every country in the world is experiencing growth in both the size and proportion of older persons in the population, and by 2030, 1 in 6 people in the world will be aged 60 years or over. Therefore, the rising demographics of the aging population are driving the growth of the transthyretin amyloidosis treatment industry.

Who Are The Major Players In The Global Transthyretin Amyloidosis Treatment Market?

Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

What Are The Key Trends Of The Global Transthyretin Amyloidosis Treatment Market? Innovative Orphan Drug Combinations Transforming The Landscape Of Transthyretin Amyloidosis Treatment

Major companies in the transthyretin amyloidosis treatment market focus on developing innovative and specialized treatments, such as orphan drugs, to enhance patient outcomes and expand treatment options. Eplontersen is an orphan drug specifically designed to treat transthyretin amyloidosis condition, often receiving regulatory benefits to support its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, received The Food and Drug Administration (FDA) approval of a new drug application for Eplontersen, an experimental orphan drug intended for the treatment of familial transthyretin-mediated amyloid, leading to progressive polyneuropathy. Eplontersen is a pharmaceutical agent developed to mitigate the synthesis of transthyretin (TTR) protein to address both the hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA granted Eplontersen orphan drug designation in 2022. `

Need data on a specific region in this market?
Request Customisation

What Are Latest Mergers And Acquisitions In The Transthyretin Amyloidosis Treatment Market? Bridgebio And Bayer Partner To Treat ATTR-CM In Europe

In April 2024, BridgeBio Pharma, a US-based biotech company, collaborated with Bayer. This partnership aimed at treating transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe. Under the deal, Bayer will exclusively commercialize the drug, with BridgeBio receiving up to $310 million in payments and royalties. This collaboration enhances the potential availability of acoramidis for patients suffering from this serious condition. Bayer is a Germany-based Life Science company.

Regional Outlook For The Global Transthyretin Amyloidosis Treatment Market

North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Transthyretin Amyloidosis Treatment Market?

The transthyretin amyloidosis treatment market consists of revenues earned by entities by providing biopsy, echocardiography, genetic testing, and imaging studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloidosis treatment market also includes sales of tolcapone, and diflunisal. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Transthyretin Amyloidosis Treatment Industry?

The transthyretin amyloidosis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the transthyretin amyloidosis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Transthyretin Amyloidosis Treatment Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $4.96 billion
Revenue Forecast In 2034 $6.83 billion
Growth Rate CAGR of 8.3% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc, Abbvie Inc, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, GSK Plc, Novo Nordisk A/S, Merck & Co. Inc, Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc, Acrotech Biopharma Inc, Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc, Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Transthyretin Amyloidosis Treatment Market Characteristics

3. Transthyretin Amyloidosis Treatment Market Trends And Strategies

4. Transthyretin Amyloidosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Transthyretin Amyloidosis Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Transthyretin Amyloidosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Transthyretin Amyloidosis Treatment Market Growth Rate Analysis

5.4. Global Transthyretin Amyloidosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Transthyretin Amyloidosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Transthyretin Amyloidosis Treatment Total Addressable Market (TAM)

6. Transthyretin Amyloidosis Treatment Market Segmentation

6.1. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN)

Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

6.2. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tafamidis

Patisiran

Inotersen

Other Drugs

6.3. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Targeted Therapy

Supportive Therapy

Pipeline Therapy

6.4. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Specialty Pharmacies

Retail Pharmacies

Online Pharmacies

6.5. Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Early-Stage ATTR-PN

Advanced-Stage ATTR-PN

6.6. Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Mild ATTR-CM

Moderate ATTR-CM

Severe ATTR-CM

7. Transthyretin Amyloidosis Treatment Market Regional And Country Analysis

7.1. Global Transthyretin Amyloidosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Transthyretin Amyloidosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Transthyretin Amyloidosis Treatment Market

8.1. Asia-Pacific Transthyretin Amyloidosis Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Transthyretin Amyloidosis Treatment Market

9.1. China Transthyretin Amyloidosis Treatment Market Overview

9.2. China Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Transthyretin Amyloidosis Treatment Market

10.1. India Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Transthyretin Amyloidosis Treatment Market

11.1. Japan Transthyretin Amyloidosis Treatment Market Overview

11.2. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Transthyretin Amyloidosis Treatment Market

12.1. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Transthyretin Amyloidosis Treatment Market

13.1. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Transthyretin Amyloidosis Treatment Market

14.1. South Korea Transthyretin Amyloidosis Treatment Market Overview

14.2. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Transthyretin Amyloidosis Treatment Market

15.1. Western Europe Transthyretin Amyloidosis Treatment Market Overview

15.2. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Transthyretin Amyloidosis Treatment Market

16.1. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Transthyretin Amyloidosis Treatment Market

17.1. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Transthyretin Amyloidosis Treatment Market

18.1. France Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Transthyretin Amyloidosis Treatment Market

19.1. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Transthyretin Amyloidosis Treatment Market

20.1. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Transthyretin Amyloidosis Treatment Market

21.1. Eastern Europe Transthyretin Amyloidosis Treatment Market Overview

21.2. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Transthyretin Amyloidosis Treatment Market

22.1. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Transthyretin Amyloidosis Treatment Market

23.1. North America Transthyretin Amyloidosis Treatment Market Overview

23.2. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Transthyretin Amyloidosis Treatment Market

24.1. USA Transthyretin Amyloidosis Treatment Market Overview

24.2. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Transthyretin Amyloidosis Treatment Market

25.1. Canada Transthyretin Amyloidosis Treatment Market Overview

25.2. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Transthyretin Amyloidosis Treatment Market

26.1. South America Transthyretin Amyloidosis Treatment Market Overview

26.2. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Transthyretin Amyloidosis Treatment Market

27.1. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Transthyretin Amyloidosis Treatment Market

28.1. Middle East Transthyretin Amyloidosis Treatment Market Overview

28.2. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Transthyretin Amyloidosis Treatment Market

29.1. Africa Transthyretin Amyloidosis Treatment Market Overview

29.2. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Transthyretin Amyloidosis Treatment Market Competitive Landscape And Company Profiles

30.1. Transthyretin Amyloidosis Treatment Market Competitive Landscape

30.2. Transthyretin Amyloidosis Treatment Market Company Profiles

30.2.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Abbvie Inc Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Transthyretin Amyloidosis Treatment Market Other Major And Innovative Companies

31.1. GSK Plc

31.2. Novo Nordisk A/S

31.3. Merck & Co. Inc

31.4. Astellas Pharma Inc.

31.5. Alexion Pharmaceuticals Inc.

31.6. Alnylam Pharmaceuticals Inc

31.7. PTC Therapeutics

31.8. Ionis Pharmaceuticals

31.9. Prothena Corporation plc

31.10. BridgeBio Pharma Inc.

31.11. Sorrento Therapeutics Inc.

31.12. Intellia Therapeutics

31.13. Akcea Therapeutics Inc.

31.14. Eidos Therapeutics Inc

31.15. Acrotech Biopharma Inc

32. Global Transthyretin Amyloidosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Transthyretin Amyloidosis Treatment Market

34. Recent Developments In The Transthyretin Amyloidosis Treatment Market

35. Transthyretin Amyloidosis Treatment Market High Potential Countries, Segments and Strategies

35.1 Transthyretin Amyloidosis Treatment Market In 2029 - Countries Offering Most New Opportunities

35.2 Transthyretin Amyloidosis Treatment Market In 2029 - Segments Offering Most New Opportunities

35.3 Transthyretin Amyloidosis Treatment Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

Need tailored insights? Customise this report to fit your business goals.

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Transthyretin Amyloidosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Transthyretin Amyloidosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Pfizer Inc Financial Performance
  • Table 78: Abbvie Inc Financial Performance
  • Table 79: Sanofi S.A. Financial Performance
  • Table 80: Bristol Myers Squibb Company Financial Performance
  • Table 81: AstraZeneca plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Transthyretin Amyloidosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Transthyretin Amyloidosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Transthyretin Amyloidosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Pfizer Inc Financial Performance
  • Figure 78: Abbvie Inc Financial Performance
  • Figure 79: Sanofi S.A. Financial Performance
  • Figure 80: Bristol Myers Squibb Company Financial Performance
  • Figure 81: AstraZeneca plc Financial Performance

Next-Gen Primary Health Care Service : Market Forecast, Transformation, and Long-Term Trajectories

Read More About Next-Gen Primary Health Care Service : Market Forecast, Transformation, and Long-Term Trajectories

Progressive Ataxia And Weakness Disorders Growth Trajectory: Key Forecasts and Strategic Insights

Read More About Progressive Ataxia And Weakness Disorders Growth Trajectory: Key Forecasts and Strategic Insights

Prostate Cancer Nuclear Medicine Diagnostics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Prostate Cancer Nuclear Medicine Diagnostics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Emerging Trends Redefining the Prostate Cancer Nuclear Medicine Diagnostics Market Landscape: Automated Parallel Capillary Electrophoresis Systems Transforming Protein Analysis In The Protein Chip Market

Read More About Emerging Trends Redefining the Prostate Cancer Nuclear Medicine Diagnostics Market Landscape: Automated Parallel Capillary Electrophoresis Systems Transforming Protein Analysis In The Protein Chip Market

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Read More About A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Read More About A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Soft Robotics Global Market Report 2025 – By Type (Soft Grippers, Cobots, Inflated Robots, Exoskeleton), By Component (Hardware, Software), By End User (Healthcare, Advanced Manufacturing, Food And Beverages, Logistics, ...

View Report

Surgical Visualization Products Global Market Report 2025 – By Product Type (Endoscopic Camera, Accessories, Light Sources, Display And Monitors, Video Recorders And Processor, Camera Heads And Video Converters), By Dist...

View Report

Tungsten Global Market Report 2025 – By Product (Carbides, Tungsten Alloys, Tungsten Mill Products, Tungsten Chemicals), By Form (Foils, Ribbons, Wires, Tubes), By End-User Industry (Automotive, Aerospace, Machine Tools ...

View Report

Methylene Diphenyl Diisocyanate (MDI)-Based Polyurethane Global Market Report 2025 – By Type (Mixed Monomeric MDI, Higher Molecular Weight Species, Other Types), By Application (Rigid Foam, Flexible Foam, Coatings, Adhes...

View Report

Chondroplasty Global Market Report 2025 – By Type (Radiofrequency Ablation Chondroplasty, Abrasion Chondroplasty, Atellar Chondroplasty, Meniscal Repair, Tissue Removal, Other Types), By Anatomy (Knee, Shoulder, Hip, Oth...

View Report

Wheel Stud Global Market Report 2025 – By Product (Screw-In Wheel Studs, Press-In Wheel studs, Welded-In Wheel Studs), By Distribution Channel (Original Equipment Manufacturer (OEM), Aftermarket), By Application (Aerospa...

View Report

Appendiceal Cancer Treatment Global Market Report 2025 – By Type (Colonic-Type Adenocarcinoma, Mucinous Adenocarcinoma Of Appendix, Goblet Cell Adenocarcinoma, Neuroendocrine Carcinoma, Other Types), By Treatment (Surger...

View Report

Paclitaxel Injection Global Market Report 2025 – By Type (Natural Paclitaxel, Semi-synthetic Paclitaxel), By Drug Strength (10mg/mL, 20mg/mL, 30mg/mL), By Indication (Breast Cancer, Prostate Cancer, Testicular Cancer, No...

View Report

Frequently Asked Questions

Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal protein deposits in the body's organs and tissues. Transthyretin amyloidosis treatment refers to the medical interventions and therapeutic strategies designed to manage and mitigate the effects of transthyretin amyloidosis (ATTR). For further insights on this market, request a sample here

The market major growth driver - Increased Research And Development Investments Propel Growth In The Transthyretin Amyloidosis Treatment Market. For further insights on this market, request a sample here

The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $4.59 billion in 2024 to $4.96 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research. The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to " $6.83 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, improved access to treatment. Major trends in the forecast period include emergence of combination therapies, strategic partnerships for drug development, focus on targeting peripheral and cardiac manifestations, implementation of patient education programs, incorporation of real-world evidence in treatment guidelines. For further insights on this market, request a sample here

The transthyretin amyloidosis treatmentmarket covered in this report is segmented –
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN); Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis; Patisiran; Inotersen; Other Drugs
3) By Therapy: Targeted Therapy; Supportive Therapy; Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Retail Pharmacies; Online Pharmacies Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN; Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM; Moderate ATTR-CM; Severe ATTR-CM For further insights on this market, request a sample here

North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A. For further insights on this market, request a sample here.

Major trends in this market include Innovative Orphan Drug Combinations Transforming The Landscape Of Transthyretin Amyloidosis Treatment. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Transthyretin Amyloidosis Treatment Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top
\
Back to top